Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 20, 2024

BUY
$16.07 - $31.84 $129,733 - $257,044
8,073 New
8,073 $233,000
Q4 2023

Feb 02, 2024

BUY
$21.58 - $29.5 $206,175 - $281,843
9,554 New
9,554 $258,000
Q4 2022

Feb 17, 2023

SELL
$25.44 - $59.78 $43,655 - $102,582
-1,716 Reduced 11.23%
13,561 $368,000
Q3 2022

Oct 26, 2022

BUY
$43.66 - $61.0 $360,238 - $503,311
8,251 Added 117.44%
15,277 $823,000
Q2 2022

Jul 22, 2022

BUY
$28.82 - $77.35 $91,128 - $244,580
3,162 Added 81.83%
7,026 $284,000
Q1 2022

Apr 22, 2022

SELL
$48.25 - $100.49 $154,255 - $321,266
-3,197 Reduced 45.28%
3,864 $255,000
Q4 2021

Feb 14, 2022

SELL
$88.71 - $120.43 $491,719 - $667,543
-5,543 Reduced 43.98%
7,061 $707,000
Q3 2021

Nov 05, 2021

SELL
$98.77 - $132.17 $201,984 - $270,287
-2,045 Reduced 13.96%
12,604 $1.58 Million
Q2 2021

Aug 16, 2021

SELL
$109.77 - $165.68 $668,828 - $1.01 Million
-6,093 Reduced 29.38%
14,649 $1.82 Million
Q1 2021

May 17, 2021

BUY
$127.04 - $179.1 $285,840 - $402,975
2,250 Added 12.17%
20,742 $3.17 Million
Q4 2020

Nov 19, 2021

SELL
$99.96 - $135.93 $296,681 - $403,440
-2,968 Reduced 13.83%
18,492 $2.38 Million
Q4 2020

Feb 18, 2021

BUY
$99.96 - $135.93 $424,430 - $577,158
4,246 Added 24.67%
21,460 $2.77 Million
Q3 2020

Nov 13, 2020

BUY
$80.32 - $111.8 $257,746 - $358,766
3,209 Added 22.91%
17,214 $1.93 Million
Q2 2020

Aug 14, 2020

BUY
$60.49 - $97.5 $247,464 - $398,872
4,091 Added 41.26%
14,005 $1.14 Million
Q1 2020

May 15, 2020

BUY
$59.04 - $88.81 $149,784 - $225,310
2,537 Added 34.39%
9,914 $690,000
Q4 2019

Feb 14, 2020

BUY
$59.49 - $82.78 $438,857 - $610,668
7,377 New
7,377 $576,000

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $3.34B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Truist Financial Corp Portfolio

Follow Truist Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Truist Financial Corp with notifications on news.